nov 7th was the cutoff for pps over $1, they had no choice on the r/s, nov 29th is the nasdaq cutoff for the $35m m cap an extension can only happen on 1 deficiency
#1. 8-K -
APRICUS BIOSCIENCES, INC. filed this Form 8-K on 05/13/2016
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On May 10, 2016, Apricus Biosciences, Inc. (the “Company”) received a Nasdaq Staff Deficiency letter indicating that, for the last thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until November 7, 2016, to regain compliance.
# 2.Item 3.01 Notice of Delisting FORM 8-K
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report June 2, 2016
On June 2, 2016, Apricus Biosciences, Inc. (the “Company”) received a notice from the NASDAQ Listing Qualifications Staff that the Company no longer satisfies the minimum $35 million market value of listed securities requirement as required for continued listing on The NASDAQ Capital Market under NASDAQ Listing Rule 5550(b)(2). However, in accordance with the NASDAQ Listing Rules, the Company has been granted a 180-day period within which to regain compliance with the market capitalization requirements, through November 29, 2016. In order to achieve compliance, the Company must evidence a market value of listed securities of at least $35 million for a minimum of 10 consecutive business days.
